News
Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...
Eli Lilly Vs. Novo Nordisk: Correction Overly Done - GLP-1 Market Leadership/ Robust Pipelines Ahead
Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...
4h
inews.co.uk on MSN‘I’m bulk buying Mounjaro ahead of price hike — it’s changed my life’
A woman who has spent over £2,000 on weight loss jabs is bulk buying Mounjaro injections ahead of a huge price hike.
Novo Nordisk said on Friday the U.S. Food and Drug Administration had granted accelerated approval for its weight-loss drug ...
Eli Lilly & Co. raises Mounjaro prices in the United Kingdom to reduce costs in the U.S. Weight-loss drug prices increase by 170% in the U.K., but its National Health Service prices remained unchanged ...
Eli Lilly recently spoke out against proposed tariffs on pharmaceuticals, warning they could increase drug costs and restrict patient access. The drugmaker said it has invested more than $50 billion ...
The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to ...
The NHS will prescribe the weight-loss jab Mounjaro to more people in response to a dramatic price increase for private ...
Texas Attorney General Ken Paxton has filed a lawsuit against U.S. pharmaceutical giant Eli Lilly, alleging the company ...
Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight, potentially transforming diabetes and obesity treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results